Literature DB >> 7946273

Oncofetal fibronectins in oral carcinomas: correlation of two different types.

U Mandel1, B Gaggero, J Reibel, M H Therkildsen, E Dabelsteen, H Clausen.   

Abstract

Different isoforms of fibronectin are derived from a single gene by alternative processing of the primary RNA transcript or by posttranslational modifications. We have previously demonstrated that an oncofetal fibronectin (FN) isoform derived by O-glycosylation is highly associated with malignancy in breast and oral tumors. Another oncofetal FN isoform containing the ED-B sequence is derived by alternative splicing, and FN containing ED-B has been found to be a stromal marker of malignancies in various tissues. Here we report a comparative study by immunohistology of the distribution of the ED-B-containing isoform and the oncofetal FN isoform derived by O-glycosylation, in oral squamous cell carcinomas, premalignant lesions, and normal oral mucosa. A selective expression of the ED-B-containing isoform was demonstrated in close relation to the invading carcinoma (38/38), whereas there was virtually no staining in submucosa underlying premalignant lesions (1/11) and normal epithelium (0/5). The ED-B-containing FN showed close co-distribution and staining pattern with the oncofetal isoform derived by O-glycosylation. These results demonstrate that accumulation of FN adjacent to oral carcinomas includes both the ED-B-containing isoform and the isoform derived by O-glycosylation. Although both the change in primary structure and glycosylation of FN create conformational and immunologically detectable changes, the functional consequences in association with invasive carcinoma are poorly understood at present. Diagnostic implications especially of borderline lesions as well as evaluation of tumor aggressiveness may, however, be important.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7946273

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

Review 1.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

Review 2.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

3.  Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants.

Authors:  U Gabler; A Berndt; H Kosmehl; U Mandel; L Zardi; S Müller; A Stelzner; D Katenkamp
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

4.  Structural insights into fibronectin type III domain-mediated signaling.

Authors:  Sompop Bencharit; Cai Bin Cui; Adnan Siddiqui; Escher L Howard-Williams; John Sondek; Kheir Zuobi-Hasona; Ikramuddin Aukhil
Journal:  J Mol Biol       Date:  2006-10-11       Impact factor: 5.469

5.  Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer.

Authors:  Ryan C Hall; Nadia R Ayat; Peter L Qiao; Amita M Vaidya; Dan Ma; Anita Aminoshariae; Ivan Stojanov; Zheng-Rong Lu
Journal:  Mol Imaging Biol       Date:  2020-08-12       Impact factor: 3.488

6.  Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma.

Authors:  H Kosmehl; A Berndt; S Strassburger; L Borsi; P Rousselle; U Mandel; P Hyckel; L Zardi; D Katenkamp
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

7.  IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).

Authors:  Petra Richter; Kerstin Junker; Marcus Franz; Angela Berndt; Christiane Geyer; Mieczyslaw Gajda; Hartwig Kosmehl; Alexander Berndt; Heiko Wunderlich
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-03       Impact factor: 4.553

Review 8.  Sweet and sour: the impact of differential glycosylation in cancer cells undergoing epithelial-mesenchymal transition.

Authors:  Leonardo Freire-de-Lima
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.